je.st
news
BIO Issues Statement on Acorda Therapeutics patent challenges.
2015-08-28 14:31:07| Industrial Newsroom - All News for Today
In addition to applauding U.S. Patent and Trademark Office's decision to reject challenges to 2 patents held by Acorda Therapeutics, BIO President and CEO Jim Greenwood stated that it remained critical for Congress and PTO to continue efforts to reform Inter Partes Review (IPR) process. This was, according to Greenwood, to ensure it operates in a balanced manner. Greenwood went on to cite 10 additional petitions submitted by Mr. Bass in the same month, an improper use of IPR system.
Tags: issues
statement
bio
challenges
Category:Industrial Goods and Services